UAE health leaders face May 2026 deadline for new WHO pathogen sharing rules

World Health Organization member states concluded three days of negotiations on 22 January 2026 to finalize the Pathogen Access and Benefit-Sharing system. This framework acts as a mandatory requirement of the WHO Pandemic Agreement established in May 2025.

For UAE healthcare executives, the system introduces transparency requirements for vaccine and diagnostic procurement. The Department of Health in Abu Dhabi and the Dubai Health Authority must track these changes. The final framework dictates the speed at which the UAE receives priority access to pathogen-based treatments during future crises.

IGWG co-chairs Ambassador Tovar da Silva Nunes and Matthew Harpur reported progress on draft annexes. The group plans to submit a final proposal to the Seventy-ninth World Health Assembly in May 2026. This schedule leaves a 4-month window for health ministries to adjust domestic supply chain policies.

Supply chain leaders and CFOs in the UAE should audit current bilateral agreements with pharmaceutical manufacturers. Once the system enters into force, drug procurement protocols shift to new multilateral standards. Operators currently use vendor contracts that require legal updates to match WHO benefit-sharing obligations. The Department of Health and the Ministry of Health and Prevention will issue local implementation circulars after the May 2026 assembly session.